FDA Determines Regulatory Review Period for Rybrevant Patent Extension

Summary

The US Food and Drug Administration (FDA) has published a notice determining the regulatory review period for Rybrevant, a human biological product, in response to a patent extension application submitted to the US Patent and Trademark Office (USPTO).